1. Home
  2. CSTE vs RNTX Comparison

CSTE vs RNTX Comparison

Compare CSTE & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CSTE

Caesarstone Ltd.

HOLD

Current Price

$1.10

Market Cap

27.7M

Sector

Industrials

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTE
RNTX
Founded
1987
2001
Country
Israel
United States
Employees
N/A
11
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
30.0M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
CSTE
RNTX
Price
$1.10
$1.23
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
2.5M
84.8K
Earning Date
03-04-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.43
N/A
Revenue Next Year
$2.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$1.02
52 Week High
$3.26
$2.22

Technical Indicators

Market Signals
Indicator
CSTE
RNTX
Relative Strength Index (RSI) 47.19 43.45
Support Level $0.86 $1.06
Resistance Level $2.00 $1.30
Average True Range (ATR) 0.18 0.11
MACD 0.04 0.00
Stochastic Oscillator 60.27 7.81

Price Performance

Historical Comparison
CSTE
RNTX

About CSTE Caesarstone Ltd.

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: